WALTHAM, Mass. – Digital therapeutics provider Glytec has been granted a patent allowance that addresses the optimization of all diabetes medications, including oral and non-insulin injectable varieties. The patent allowance, issued by the United States Patent and Trademark Office, comprises a series of 24 claims that describe personalized computer-guided selection and dosing of any prescribed diabetes therapy regimen, whether insulin only, non-insulin only or combination. “Evidence shows that providers demonstrate wide variation in the choice and sequence of diabetes medications, and in spite of some 100 medications currently available in the U.S. to treat diabetes, only about half of all patients with diabetes achieve their treatment goals,” said Dr. Andrew Rhinehart, chief medical officer at Glytec, in a statement. “We are developing solutions that will remove the guesswork and make it much simpler for providers to identify what will work best for each individual patient, ultimately helping root out billions of dollars in wasted pharmaceutical expense and driving better outcomes.” Glytec is also developing a new product, Therapy Advisor, to facilitate the optimization of all diabetes medications and aid providers with diabetes management in the outpatient setting and at the time of transition from hospital to home.
You are here: / / Glytec granted patent allowance for computer-guided selection and dosing of diabetes medications